tiprankstipranks
Trending News
More News >
Wuhan YZY Biopharma Co., Ltd. Class H (HK:2496)
:2496
Hong Kong Market
Advertisement

Wuhan YZY Biopharma Co., Ltd. Class H (2496) Income Statement

Compare
1 Followers

Wuhan YZY Biopharma Co., Ltd. Class H Income Statement

Last quarter (Q2 2025), Wuhan YZY Biopharma Co., Ltd. Class H's total revenue was ¥22.18M, an increase of 1465.24% from the same quarter last year. In Q2, Wuhan YZY Biopharma Co., Ltd. Class H's net income was ¥-29.42M. See Wuhan YZY Biopharma Co., Ltd. Class H’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21
Total Revenue
¥ 107.81M¥ 11.92M¥ 2.26M¥ 12.18M
Gross Profit
¥ 85.07M¥ 11.92M¥ 2.26M¥ 12.18M
Operating Expenses
¥ 183.07M¥ 177.37M¥ 177.85M¥ 144.39M
Depreciation and Amortization
¥ 6.57M¥ 6.39M¥ 6.34M¥ 7.03M
EBITDA
¥ -86.95M¥ -158.39M¥ -169.23M¥ -125.20M
Operating Income
¥ -98.00M¥ -177.37M¥ -175.58M¥ -132.23M
Other Income/Expenses
¥ 402.00K¥ -14.34M¥ -13.29M¥ -16.29M
Pretax Income
¥ -97.60M¥ -190.98M¥ -188.87M¥ -148.52M
Net Income
¥ -97.60M¥ -190.98M¥ -188.87M¥ -148.52M
Per Share Metrics
Basic EPS
¥ -0.50¥ -1.14¥ -0.98¥ -0.77
Diluted EPS
¥ -0.50¥ -1.14¥ -0.98¥ -0.77
Weighted Average Shares Outstanding
193.85M 185.11M 193.00M 193.00M
Weighted Average Shares Outstanding (Diluted)
193.85M 185.11M 193.00M 193.00M
Currency in CNY

Wuhan YZY Biopharma Co., Ltd. Class H Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis